Abbott (ABT), Reckitt Unit Defeat Infant-formula Sickness Claims - Bloomberg
Tweet
Share
E-mail
Get Alerts ABT Hot Sheet
Price: $108.33 -0.42%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.8%
Revenue Growth %: +14.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.8%
Revenue Growth %: +14.2%
Join SI Premium – FREE
Abbott (NYSE: ABT), Reckitt Unit Defeat Infant-formula Sickness Claims - Bloomberg
- Abbott, Reckitt Trial Victory Is First In Infant-formula Cases
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADARx Pharmaceuticals files for proposed IPO
- Bank of America to redeem CAD1.425 billion in Canadian senior notes
- USA Rare Earth (USAR) files $1.25B mixed shelf
Create E-mail Alert Related Categories
Corporate News, Hot Corp. News, LitigationRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
